Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

This phase 2 trial investigated reinduction with carfilzomib, pomalidomide, and dexamethasone (KPd) and continuous pomalidomide/dexamethasone in patients at first progression during lenalidomide maintenance. The second objective was to evaluate high-dose melphalan with autologous stem cell transplan...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonneveld, Pieter, Zweegman, Sonja, Cavo, Michele, Nasserinejad, Kazem, Broijl, Annemiek, Troia, Rosella, Pour, Ludek, Croockewit, Sandra, Corradini, Paolo, Patriarca, Francesca, Wu, Kalung, Droogendijk, Jolanda, Bos, Gerard, Hajek, Roman, Teresa Petrucci, Maria, Ypma, Paula, Zojer, Nicholas, Minnema, Monique C., Boccadoro, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529060/
https://www.ncbi.nlm.nih.gov/pubmed/36204691
http://dx.doi.org/10.1097/HS9.0000000000000786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529060/
https://www.ncbi.nlm.nih.gov/pubmed/36204691
http://dx.doi.org/10.1097/HS9.0000000000000786

Ejemplares similares